Index Entries

P. Bigini, M. Gobbi, M. Bnati, A. Clavenna, M. Zucchetti, S. Garattini, and G. Pasut
November 4, 2021
Nature Nanotechnology
Istituto di Ricerche Farmacologiche Mario Negri (Italy)

Commentary article

document
adverse events,COVID-19,lipid nanoparticles,mRNA,vaccine ingredients,vaccines